NASDAQ:MNKD - MannKind Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.01 +0.05 (+2.55 %)
(As of 06/24/2018 04:00 PM ET)
Previous Close$2.01
Today's Range$1.87 - $2.03
52-Week Range$1.09 - $6.96
Volume20.91 million shs
Average Volume1.88 million shs
Market Capitalization$274.45 million
P/E Ratio-1.73
Dividend YieldN/A
Beta2.79
MannKind logoMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000

Debt

Debt-to-Equity Ratio-0.43
Current Ratio0.43
Quick Ratio0.39

Price-To-Earnings

Trailing P/E Ratio-1.73
Forward P/E Ratio-2.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.74 million
Price / Sales23.97
Cash FlowN/A
Price / CashN/A
Book Value($1.81) per share
Price / Book-1.11

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-117,330,000.00
Net Margins-1,076.91%
Return on EquityN/A
Return on Assets-185.01%

Miscellaneous

Employees250
Outstanding Shares140,020,000

The Truth About Cryptocurrencies

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The biopharmaceutical company had revenue of $3.47 million for the quarter, compared to analysts' expectations of $3.53 million. During the same quarter in the prior year, the company posted ($0.17) EPS. View MannKind's Earnings History.

When is MannKind's next earnings date?

MannKind is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for MannKind.

What price target have analysts set for MNKD?

2 analysts have issued 1 year price targets for MannKind's shares. Their predictions range from $1.00 to $5.00. On average, they expect MannKind's stock price to reach $2.9233 in the next year. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:
  • 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (5/24/2018)
  • 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) $324.5 Market Cap (M) $238 Shares Outstanding (M) 133.1 3 Interest (M) 32.53 Cash (M) $53.5 Total Debt (M) $140.0 Year – (0.15) FY (1.13) (0.83) (0.65) FY P/E NM NM NM Year – 14.7 FY 11.7 20.8 45.4 8 6 4 2 0 0 Vol. (mil) the science to drive Afrezza awareness and adoption." (5/10/2018)

Are investors shorting MannKind?

MannKind saw a decrease in short interest in the month of May. As of May 31st, there was short interest totalling 29,044,004 shares, a decrease of 4.0% from the May 15th total of 30,255,708 shares. Based on an average daily volume of 1,761,471 shares, the short-interest ratio is currently 16.5 days. Currently, 23.0% of the company's stock are short sold. View MannKind's Current Options Chain.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:
  • Dr. Michael E. Castagna, CEO & Director (Age 41)
  • Dr. David B. Thomson, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 55)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
  • Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)

Has MannKind been receiving favorable news coverage?

News stories about MNKD stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MannKind earned a media sentiment score of 0.03 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.49 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are MannKind's major shareholders?

MannKind's stock is owned by a number of of institutional and retail investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.57%), BlackRock Inc. (2.62%), Scopia Capital Management LP (0.81%), Millennium Management LLC (0.74%), Tibra Equities Europe Ltd (0.20%) and Dupont Capital Management Corp (0.20%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.

Which major investors are selling MannKind stock?

MNKD stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and BlackRock Inc.. View Insider Buying and Selling for MannKind.

Which major investors are buying MannKind stock?

MNKD stock was purchased by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Millennium Management LLC, Tibra Equities Europe Ltd, Element Capital Management LLC, Dupont Capital Management Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya and Stuart A Tross. View Insider Buying and Selling for MannKind.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $2.01.

How big of a company is MannKind?

MannKind has a market capitalization of $274.45 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]


MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  390 (Vote Outperform)
Underperform Votes:  504 (Vote Underperform)
Total Votes:  894
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.